FOGHORN THERAPEUTICS I
4.3000
14-May-25 09:30:05
15 minutes delayed
Stocks
-0.0300
-0.69%
Today's range
4.3000 - 4.3000
ISIN
N/A
Source
NASDAQ
-
Foghorn Therapeutics Announces First Patient Dosed in First-in-Human Clinical Trial of FHD-609
23 Aug 2021 07:00:00 By Nasdaq GlobeNewswire
-
Foghorn Therapeutics Provides Second Quarter 2021 Corporate Update
10 Aug 2021 07:00:02 By Nasdaq GlobeNewswire
-
Foghorn Therapeutics to Participate at the 2021 Wedbush PacGrow Healthcare Virtual Conference
03 Aug 2021 08:30:00 By Nasdaq GlobeNewswire
-
Foghorn Therapeutics to Participate at the William Blair Biotech Focus Conference 2021
09 Jul 2021 08:36:31 By Nasdaq GlobeNewswire
-
Foghorn Therapeutics to Host Research & Development Day Webinar on June 15th
08 Jun 2021 07:00:01 By Nasdaq GlobeNewswire
-
Foghorn Therapeutics to Present in Two Upcoming Investor Conferences
26 May 2021 08:00:03 By Nasdaq GlobeNewswire
-
Foghorn Therapeutics Announces Dosing of First Patient in First-in-Human Clinical Program of FHD-286
17 May 2021 07:00:01 By Nasdaq GlobeNewswire
-
Foghorn Therapeutics Provides Corporate Update
11 May 2021 07:00:02 By Nasdaq GlobeNewswire
-
Foghorn Therapeutics Appoints Ian Smith to its Board of Directors
28 Apr 2021 07:00:00 By Nasdaq GlobeNewswire
-
Foghorn Therapeutics Provides Corporate Update
18 Mar 2021 08:00:00 By Nasdaq GlobeNewswire
-
UPDATE: Foghorn Therapeutics to Present Poster and Chair a Panel at the AACR Annual Meeting 2021
11 Mar 2021 17:11:35 By Nasdaq GlobeNewswire
-
Foghorn Therapeutics to Present Poster and Chair a Panel and at the AACR Annual Meeting 2021
11 Mar 2021 16:01:00 By Nasdaq GlobeNewswire